BSE Live
Sep 24, 16:01Prev. Close
1084.00
Open Price
1076.10
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Sep 24, 15:55Prev. Close
1084.80
Open Price
1084.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
1080.30 (331)
Profit & Loss account of Jubilant Pharmova (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
INCOME | ||||||
Revenue From Operations [Gross] | 734.00 | 755.20 | 774.42 | 87.75 | 2,688.07 | |
Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Revenue From Operations [Net] | 734.00 | 755.20 | 774.42 | 87.75 | 2,688.07 | |
Total Operating Revenues | 745.70 | 784.70 | 810.12 | 87.75 | 2,709.50 | |
Other Income | 99.60 | 103.40 | 137.89 | 125.87 | 47.88 | |
Total Revenue | 845.30 | 888.10 | 948.01 | 213.62 | 2,757.38 | |
EXPENSES | ||||||
Cost Of Materials Consumed | 282.50 | 310.00 | 396.30 | 0.00 | 1,328.92 | |
Purchase Of Stock-In Trade | 0.00 | 6.50 | 14.81 | 0.00 | 66.23 | |
Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Changes In Inventories Of FG,WIP And Stock-In Trade | -6.70 | 39.00 | 3.45 | 0.00 | 55.21 | |
Employee Benefit Expenses | 203.00 | 190.00 | 167.27 | 49.21 | 220.67 | |
Finance Costs | 29.80 | 29.90 | 18.52 | 30.59 | 101.80 | |
Depreciation And Amortisation Expenses | 53.10 | 48.30 | 43.25 | 6.25 | 99.97 | |
Other Expenses | 234.80 | 222.70 | 225.07 | 45.32 | 611.41 | |
Total Expenses | 796.50 | 846.40 | 868.67 | 131.37 | 2,484.21 | |
Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 48.80 | 41.70 | 79.34 | 82.25 | 273.17 | |
Exceptional Items | -11.20 | 0.00 | 0.00 | 0.00 | 0.00 | |
Profit/Loss Before Tax | 37.60 | 41.70 | 79.34 | 82.25 | 273.17 | |
Tax Expenses-Continued Operations | ||||||
Current Tax | 19.80 | 6.80 | 13.82 | 13.66 | 45.44 | |
Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Deferred Tax | -1.40 | 3.30 | 15.64 | -9.91 | 13.25 | |
Tax For Earlier Years | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Total Tax Expenses | 18.40 | 10.10 | 29.46 | 3.75 | 58.69 | |
Profit/Loss After Tax And Before ExtraOrdinary Items | 19.20 | 31.60 | 49.88 | 78.50 | 214.48 | |
Profit/Loss From Continuing Operations | 19.20 | 31.60 | 49.88 | 78.50 | 214.48 | |
Profit/Loss For The Period | 19.20 | 31.60 | 49.88 | 78.50 | 214.48 | |
OTHER ADDITIONAL INFORMATION | ||||||
EARNINGS PER SHARE | ||||||
Basic EPS (Rs.) | 1.21 | 1.99 | 3.13 | 4.93 | 13.47 | |
Diluted EPS (Rs.) | 1.21 | 1.99 | 3.13 | 4.93 | 13.47 | |
VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
Imported Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Indigenous Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
STORES, SPARES AND LOOSE TOOLS | ||||||
Imported Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Indigenous Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
Equity Share Dividend | 79.60 | 79.60 | 79.64 | 79.64 | 0.00 | |
Tax On Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Equity Dividend Rate (%) | 500.00 | 500.00 | 500.00 | 500.00 | 500.00 |
30.07.2025
Jubilant Pharmo Consolidated June 2025 Net Sales at Rs 1,900.70 crore, up 9.76% Y-o-Y
30.07.2025
Jubilant Pharmo Standalone June 2025 Net Sales at Rs 59.50 crore, down 64.31% Y-o-Y
20.07.2025
16.06.2025
30.07.2025
Jubilant Pharmo Consolidated June 2025 Net Sales at Rs 1,900.70 crore, up 9.76% Y-o-Y
30.07.2025
Jubilant Pharmo Standalone June 2025 Net Sales at Rs 59.50 crore, down 64.31% Y-o-Y
16.05.2025
Jubilant Pharmo Consolidated March 2025 Net Sales at Rs 1,928.80 crore, up 9.68% Y-o-Y
16.05.2025
Jubilant Pharmo Standalone March 2025 Net Sales at Rs 217.30 crore, up 5.59% Y-o-Y
18.01.2021
Jubilant Life Sciences Q3 PAT seen up 14.9% YoY to Rs. 238 cr: Prabhudas Lilladher
12.07.2019
Jubilant Life Sciences Q1 PAT may dip 10.4% YoY to Rs. 181.4 cr: Prabhudas Lilladher
12.04.2019
Jubilant Life Sciences Q4 PAT seen up 36.3% YoY to Rs. 211.2 cr: Prabhudas Lilladher
11.01.2019
Jubilant Life Science Q3 PAT seen up 13.8% YoY to Rs. 241.8 cr: ICICI Direct